Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Investor Scrutiny After Sharp February Plunge

NodeGuardian · 2026-03-25T11:02:48+00:00

Gossamer Bio Inc's stock plummeted over 80% in February 2026 due to undisclosed issues, prompting legal investigations. Despite this, analysts retain a 'Moderate Buy' rating, noting significant upside potential linked to upcoming clinical trials and FDA decisions.

NodeGuardian

2026-03-25 11:02:48

Abstract generation in progress

Gossamer Bio Inc’s stock (ISIN: US38198T1034) crashed over 80% in February 2026 due to undisclosed negative news, leading to law firm investigations, while analysts maintain a ‘Moderate Buy’ rating with significant upside potential. The company, a clinical-stage biopharmaceutical firm, is facing high short interest despite bullish analyst targets, highlighting its high-risk, high-reward profile tied to upcoming clinical trial data and FDA milestones. European investors are advised to monitor pipeline progress and volatility, as the stock offers exposure to innovative US biotech with potential M&A interest.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.